Ozempic is named as an intervention in 12 current clinical trials in our Canada, Denmark, Belgium, Sweden, Switzerland and South Korea registers. 7 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is Universitaire Ziekenhuizen KU Leuven (1). The most-studied condition is Glucose Intolerance After a Recent History of Gestational Diabetes.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Glucose Intolerance After a Recent History of Gestational Diabetes | 1 |
| Prostate Cancer | 1 |
| Obesity (Disorder) | 1 |
| Type2 Diabetes | 1 |
| Acute Ischemic Stroke | 1 |
| Type 2 DM | 1 |
| Type 2 DM /Diabetic Nephropathy | 1 |
| Albuminuria | 1 |
| Foot Ulcer Due to Type 2 Diabetes Mellitus | 1 |
| Klinefelter Syndrome | 1 |
| Class I/II Obesity | 1 |
| Obesity | 1 |
| Chronic Kidney Disease | 1 |
| Kidney Transplant Recipients | 1 |
| Diabetes Mellitus, Type 2 | 1 |
| Lead sponsor | Trials |
|---|---|
| Universitaire Ziekenhuizen KU Leuven | 1 |
| Hamilton Health Sciences Corporation | 1 |
| McMaster University | 1 |
| Region Skane | 1 |
| Aarhus University Hospital | 1 |
| Steno Diabetes Center Copenhagen | 1 |
| Ole Lander Svendsen | 1 |
| Georgios Papadakis | 1 |
| Alain Dagher | 1 |
| Western University, Canada | 1 |
| University Health Network, Toronto | 1 |
| Novo Nordisk A/S | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Canada | 5 | 3 |
| Clinical trials in Denmark | 3 | 2 |
| Clinical trials in Belgium | 1 | 1 |
| Clinical trials in Sweden | 1 | 0 |
| Clinical trials in Switzerland | 1 | 1 |
| Clinical trials in South Korea | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
12 current trials in our Canada, Denmark, Belgium, Sweden, Switzerland and South Korea registers name Ozempic as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 7 of the 12 trials are recruiting: 3 with sites in Canada, 2 with sites in Denmark, 1 with sites in Belgium and 1 with sites in Switzerland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Universitaire Ziekenhuizen KU Leuven (1), Hamilton Health Sciences Corporation (1), McMaster University (1) and Region Skane (1), among 12 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Ozempic works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Ozempic works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Ozempic (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.